Using MALDI-TOF mass spectrometry in peripheral blood for the follow up of newly diagnosed multiple myeloma patients treated with daratumumab-based combination therapy.

CONCLUSION: MALDI-TOF MS is useful in assessing CR in patients treated with monoclonal antibody-based therapies.
PMID: 33545108 [PubMed - as supplied by publisher]

Source: International Journal of Clinical Chemistry - February 2, 2021 Category: Chemistry Authors: Eveillard M, Korde N, Ciardiello A, Diamond B, Lesokhin A, Mailankody S, Smith E, Hassoun H, Hultcrantz M, Shah U, Lu S, Salcedo M, Werner K, Rispoli J, Mastey D, Landgren O, Thoren K Tags: Clin Chim Acta Source Type: research